# A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

> **NCT06060457** · PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 1900 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** Fluzone HD

## Key facts

- **NCT ID:** NCT06060457
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-25
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-06-07
- **Target enrollment:** 1900 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06060457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06060457, "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06060457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*